Table 2. The efficacy of standard triple therapy with different durations of administration .

Year	City	Therapy	Treatment duration (days)	Number of patients.	Underlying disease	Eradication assessment method.	Duration from therapy (week)	Per-protocol eradication rate
2003	Ardabi24	OAC	7	45	Gastritis	UBT	8	42
2006	Tehran25	OAC	7	120	H. pylori (+)	UBT	6	91.8
2012	Kerman26	OPC	7	34	H. pylori (+)	?	?	73
2010	Rasht27	OAC	10	107	NUD	Stool Antigen	8	90.7
2010	Tehran28	OAC	10	104	PUD	UBT	8	90.4
2013	Ghom29	OAC	10	76	H. pylori (+)	UBT	6	83
2013	Ahvaz30	OAC LAC EAC	10	98 97 98	H. pylori (+)	UBT	6	91.9 80.4 91.8
2015	Ahvaz31	OAC	10	100	H. pylori (+)	UBT	8	93.9
2007	Kermashah32	OAC (C: half dose) OAC	14 14	53 53	H. pylori (+)	UBT	6	88 89
2009	Yazd35	OAC	14	53	H. pylori (+)	UBT	4 - 6	70
2013	Shiraz34	OAC OPC	14	110 110	PUD	UBT	6	90.8 87
2014	Tehran33	OAC	14	39	GU	Biopsy	8	82.9
2015	Tehran36	OAC OAC	14 14 (A:28)	33 33	H. pylori (+)	Stool Antigen	4	63.6 90.9

O: Omeprazole, L: Lansoprazole, P: Pantoprazole, E: Esomeprazole, Amox: Amoxicillin, Cla: Clarithromycin, GU: Gastric ulcer, PUD: Peptic ulcer disease, NUD: Non-ulcer dyspepsia,

UBT: Urea breath test